文献速递心力衰竭与心肌病

药物降压在射血分数轻度降低或保留心衰中的效果:一项荟萃分析

Effects of pharmacological blood pressure lowering in heart failure with mildly reduced or preserved ejection fraction: a meta-analysis.
PubMed 文献 · Heart · 2026-08-07

药物降压显著降低心血管死亡与心衰住院复合终点(RR 0.86, 95%CI 0.83-0.89; p≤0.001),但药物类别间存在显著差异(p=0.018),且降压幅度与治疗效果无显著关联。

要点

  • SGLT2i、MRA、ARNI和GLP-1RA显示获益,其他药物类别未显示。
  • 降压幅度与临床获益无显著关联,提示获益不完全由降压介导。

核心结论

  • 在HFmrEF/HFpEF患者中,药物降压与临床结局之间无显著关联,提示单纯降压不太可能解释近期确立的心衰治疗的全部获益。

研究设计与样本

  • 采用随机效应荟萃分析和逆方差加权荟萃回归,效应量以风险比(RR)及其95%CI表示。

主要发现

  • 药物降压显著降低主要复合终点(心血管死亡和心衰住院)(RR 0.86, 95%CI 0.83-0.89; p≤0.001)。
  • 药物类别间存在显著差异(p=0.018),SGLT2i、MRA、ARNI和GLP-1RA显示获益,其他药物类别未显示。
  • 荟萃回归未发现降压幅度与治疗效果之间存在显著关联(系数斜率=-0.0125, p=0.304)。
  • 药物降压与心衰住院减少相关(RR 0.83, 95%CI 0.79-0.86; p≤0.001),但治疗效果与降压幅度无关(系数斜率=-0.0121, p=0.528)。

临床怎么用

  • 在HFmrEF/HFpEF患者中,不应仅以降压幅度为目标来选择心衰治疗药物。
  • 优先选用有证据获益的药物类别(SGLT2i、MRA、ARNI、GLP-1RA),而非单纯依赖降压效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of blood pressure (BP) lowering in patients with heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) remains uncertain, and it is unclear to what extent the existing benefits of therapies are mediated by BP reduction. METHODS AND RESULTS: A systematic review and meta-analysis of randomised clinical trials was conducted, comparing any BP lowering treatment to placebo, usual care or another drug class in patients with HFmrEF/HFpEF. The primary endpoint was a composite of cardiovascular death and HF hospitalisation. Data were pooled using a random effects meta-analysis and meta-regression with inverse variance weighting expressed as a risk ratio (RR) and its 95% CI. 18 studies were identified totalling 39 452 patients. Pharmacological BP lowering led to a significant reduction in the primary composite endpoint (RR 0.86, 95% CI 0.83 to 0.89; p≤0.001), but there were significant differences between drug classes (p value=0.018), with evidence of benefit with sodium-glucose cotransporter 2 inhibitor, mineralocorticoid receptor antagonist, angiotensin-receptor neprilysin inhibitor and glucagon-like peptide-1 receptor agonists but not other drug classes. Meta-regressions found no significant association between the degree of BP reduction and treatment effects (coefficient slope=-0.0125, p=0.304). Similarly, pharmacological BP lowering was associated with a reduction in HF hospitalisations (RR 0.83, 95% CI 0.79 to 0.86; p≤0.001), but treatment effects were not related to degree of BP reduction (coefficient slope=-0.0121, p=0.528). CONCLUSION: In patients with HFmrEF/HFpEF, there was no significant association between pharmacological BP lowering and clinical outcomes, suggesting that BP lowering alone is unlikely to explain all the benefits observed with the use of recently established HF therapies. PROSPERO REGISTRATION NUMBER: CRD42025631539.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Pack, Sawant, Abhayaratna, et al. Effects of pharmacological blood pressure lowering in heart failure with mildly reduced or preserved ejection fraction: a meta-analysis. Heart. 2026. PMID: 42571647. doi:10.1136/heartjnl-2026-327872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。